| SEC For   |   |  |   |         |  |  |            | וידים                                   |                      |  | EVOLIA                        |   |   |  |  |   |   |                                       |  |
|---|---|--|---|---------|--|--|------------|---|----------------------|--|-------------------------------|---|---|--|--|---|---|---------------------------------------|--|
| FORM 4 UNITED STAT  |   |  |   |         | AIE  | TES SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549   |            |   |                      |  |                               |   |   |  |  | OMB APPROVAL                                      |   |                                       |  |
| Section 16. Form 4 or Form 5<br>obligations may continue. See                                   |   |  |   |         |  | NT OF CHANGES IN BENEFICIAL OWNERSHIP  |            |   |                      |  |                               |   |   |  |  | OMB Number: 3235-0287<br>Estimated average burden |   |                                       |  |
|   |   |  |   |         |  | l pursuant to Section 16(a) of the Securities Exchange Act of 1934<br>or Section 30(h) of the Investment Company Act of 1940 |            |   |                      |  |                               |   |   |  |  | hours per response: 0.                            |   |                                       |  |
| 1. Name and Address of Reporting Person<br>Deschatelets Pascal                                  |   |  |   |         |  | 2. Issuer Name and Ticker or Trading Symbol<br><u>Apellis Pharmaceuticals, Inc.</u> [ APLS ]                                 |            |   |                      |  |                               |   |   | Relationship<br>heck all applic<br>Directo           | cable)   | eporting Person(s) to Issuer<br>e)<br>10% Owne    |   |                                       |  |
| (Last) (First) (Middle)<br>C/O APELLIS PHARMACEUTICALS, INC.                                    |   |  |   |         | 3. Date of Earliest Transaction (Month/Day/Year) X<br>05/08/2024 |  |            |   |                      |  |                               |   | A below)  | Officer (give title<br>below)<br>Chief Scientific Of |  |   | pecify  |                                       |  |
| 100 FIFTH AVENUE, 3RD FLOOR (Street)  |   |  |   |         | 4.   | 4. If Amendment, Date of Original Filed (Month/Day/Year)<br>Line)<br>X   |            |   |                      |  |                               |   |   | ie)<br>X Form f                                      | vidual or Joint/Group Filing (Check Applicable<br>Form filed by One Reporting Person                           |   |   |                                       |  |
| WALTH   | AM M  | Α  | 02451                                   |         |  |  |            |   |                      |  |                               |   |   |  | Form filed by More than One Reporting Person   |   |   |                                       |  |
| (City) (State) (Zip)  |   |  |   | -   R   | Rule 10b5-1(c) Transaction Indication                            |  |            |   |                      |  |                               |   |   |  |  |   |   |                                       |  |
|   |   | Tak  |   | lan Dar |  | satis  | fy the a   | affirmativ                              | ve defen             | se con   | ansaction was ditions of Rule | 10b5-1(c).  | See Instruct  | tion 10.   |  | i plan that                                       | is intended   | d to                                  |  |
| Table I - Non-Deriva       1. Title of Security (Instr. 3)     2. Transactio Date (Month/Day/N) |   |  |   | tion    | n 2A. Deemed<br>Execution Date.                                  |  | d<br>Date, | 3.<br>Transaction<br>Code (Instr.<br>8) |                      | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 ar |                               | (A) or  | 5) 5. Amount of<br>Securities<br>Beneficially<br>Owned Followir |  | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>g (I) (Instr. 4)  |   | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership               |                                       |  |
|   |   |  |   |         |  |  |            |   | Code                 | v  | Amount                        | (A) or<br>(D)   | Price   | Reporte<br>Transac<br>(Instr. 3                      | tion(s)  |   |   | Instr. 4)                             |  |
| Common Stock 05/08/2  |   |  |   | 2024    | )24  |  |            | <b>M</b> <sup>(1)</sup>                 |                      | 78,907   | Α                             | \$4.31  | 1,19  | 1,194,890  |  | >   |   |                                       |  |
| Common Stock 05/08/   |   |  |   | .024    |  |  |            | <b>S</b> <sup>(1)</sup>                 |                      | 56,335   | D                             | \$42.150  | 4 <sup>(2)</sup> 1,13   | 38,555   |  |   |   |                                       |  |
| Common Stock 05/08/20   |   |  |   | 2024    | 24   |  |            | <b>S</b> <sup>(1)</sup>                 |                      | 22,472   | D                             | \$42.849  | (3) 1,11  | 1,116,083  |  |   |   |                                       |  |
| Common Stock 05/08/202  |   |  |   |         | 2024   | 24   |            |   | s <sup>(1)</sup> 100 |  | D                             | \$44.02   | 5 1,115,983   |  |  | >   |   |                                       |  |
|   |   |  | Table I                                 |         |  |  |            |   |                      |  | sposed of,<br>, converti      |   |   | y Owned  |  |   |   |                                       |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any |         | 4.<br>Transa   | 4.<br>Transaction<br>Code (Instr.  |            | 5. Number                               |                      |  | cisable and<br>Date           | 7. Title and Am<br>of Securities<br>Underlying<br>Derivative Sect<br>(Instr. 3 and 4) |   | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)  | 9. Numbe<br>derivative<br>Securities<br>Beneficia<br>Owned<br>Following<br>Reported<br>Transacti<br>(Instr. 4) | e O<br>s Fo<br>lly Di<br>or<br>g (l)              | D.<br>wnership<br>orm:<br>irect (D)<br>r Indirect<br>) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4) |  |
|   |   |  |   |         | Code   | v  | (A)        | (D)                                     | Date                 | isable   | Expiration<br>Date            | Title   | Amount<br>or<br>Number<br>of<br>Shares                          | 1  |  |   |   |                                       |  |

## Explanation of Responses:

\$4.31

Stock

Buy)

Option (Right to

1. This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.

05/08/2024

2. This transaction was executed in multiple trades at prices ranging from \$41.575 - \$42.570. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(4)

78,907

3. This transaction was executed in multiple trades at prices ranging from \$42.575 - \$43.545. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This stock option was granted on 08/21/2017 and is fully vested.

| /s/ David Watson, attorney-in- | 05/09/2024 |
|--------------------------------|------------|
| fact for Pascal Deschatelets   | 03/09/2024 |

108,622

D

\*\* Signature of Reporting Person Date

78,907

\$<mark>0</mark>

Commor Stock

08/22/2027

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**M**<sup>(1)</sup>

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.